[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100331390":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":54,"centralContacts":58,"locations":64,"responsibleParty":81,"collaborators":83,"id":87,"slug":46,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":91,"acronym":46,"eligibilityCriteria":92,"healthyVolunteers":88,"sex":93,"minAge":94,"maxAge":46,"enrollmentInfo":95,"targetDuration":46,"studyType":98,"phases":99,"briefSummary":101,"conditions":102,"keywords":46,"overallStatus":67,"whyStopped":46,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":121},{"fullName":5,"class":6},"M.D. Anderson Cancer Center","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Group I (surgical resection)","ACTIVE_COMPARATOR","Participants who have achieved clinical complete response undergo standard surgical resection.",[13,14],"Other: Questionnaire Administration","Procedure: Resection of Rectum",{"label":16,"type":17,"description":18,"interventionNames":19},"Group II (active surveillance)","EXPERIMENTAL","Participants who have achieved clinical complete response receive active surveillance and consolidated chemotherapy for up to 4 months in the absence of disease progression or unacceptable toxicity. Participants with incomplete response or regrowth of tumor, undergo surgical resection as in Group I.",[20,21,13,14],"Drug: Chemotherapy","Other: Patient Observation",[23,32,42,47],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Chemotherapy","Receive chemotherapy",[16],[29,30,31],"Chemo","Chemotherapy (NOS)","Chemotherapy, Cancer, General",{"type":6,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"Patient Observation","Receive active surveillance",[16],[37,38,39,40,41],"Active Surveillance","deferred therapy","expectant management","observation","Watchful Waiting",{"type":6,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Questionnaire Administration","Ancillary studies",[9,16],null,{"type":48,"name":49,"description":50,"armGroupLabels":51,"otherNames":52},"PROCEDURE","Resection of Rectum","Undergo surgical resection",[9,16],[53],"Proctectomy",[55],{"name":56,"affiliation":5,"role":57},"George Chang","PRINCIPAL_INVESTIGATOR",[59],{"name":60,"role":61,"phone":62,"phoneExt":46,"email":63},"George J. Chang","CONTACT","713-792-6940","gchang@mdanderson.org",[65],{"facility":66,"status":67,"city":68,"state":69,"zip":70,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":78,"contacts":79},"M D Anderson Cancer Center","RECRUITING","Houston","Texas","77030","United States","US",{"type":74,"coordinates":75},"Point",[76,77],-95.36327,29.76328,{"lat":77,"lon":76},[80],{"name":46,"role":61,"phone":46,"phoneExt":46,"email":63},{"type":82,"investigatorFullName":46,"investigatorTitle":46,"investigatorAffiliation":46,"oldNameTitle":46,"oldOrganization":46},"SPONSOR",[84],{"name":85,"class":86},"National Cancer Institute (NCI)","NIH","100331390",false,"NCT03594630","Active Surveillance and Chemotherapy Before Surgery in Treating Participants With Stage II-III Rectal Cancer","Organ Preservation With Active Surveillance After Chemoradiation in Rectal Cancer (OPTION)","Inclusion Criteria:\n\n* Histologically confirmed diagnosis of rectal adenocarcinoma\n* Eligible for curative resection of rectal adenocarcinoma\n* Rectal tumor location =\\\u003C 12 cm from the anal verge as determined by endoscopy or magnetic resonance imaging (MRI) (if endoscopy report is not available or deemed inadequate my treating oncologist)\n* Nodal involvement confined to the radiation field\n* Radiologically measurable or clinically evaluable disease as defined in the protocol\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS): 0, 1 or 2\n* Clinical Stage: Stage II and III. N2 disease is to be estimated as four or more lymph nodes that are \\>= 10 mm. Clinical staging should be estimated based on the combination of the following assessments: physical exam by the primary surgeon including digital rectal exam (DRE), computed tomography (CT) or positron emission tomography (PET)\u002FCT scan of the chest\u002Fabdomen\u002Fpelvis and a pelvic MRI. If a pelvic MRI is performed, it is acceptable to perform CT of the chest\u002Fabdomen, omitting CT imaging of the pelvis. PET\u002FCT is optional.\n* No known contraindication to standard (fluoropyrimidine-based) pelvic chemoradiation (e.g. dihydropyrimidine dehydrogenase \\[DPD\\] deficiency)\n* Patient of child-bearing potential is willing to employ adequate contraception during treatment and after treatment, as directed by treating clinical team\n* Willing to provide written informed consent\n* Willing to return to enrolling medical site for all study assessments\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory bowel disease (IBD)\n* Diagnosis of MSI-H colorectal cancer at time of consent\n* Recurrent rectal cancer\n* Tumor is causing symptomatic bowel obstruction (patients who have diverting ostomy are eligible)\n* Any prior pelvic radiation\n* Other invasive malignancy undergoing active treatment. Patients receiving prior treatment that precludes standard chemoradiation or ability to receive consolidation\u002Fadjuvant chemotherapy will be excluded from survival analyses\n* Patients unwilling or unable to undergo pelvic MRI","ALL","18 Years",{"count":96,"type":97},120,"ESTIMATED","INTERVENTIONAL",[100],"EARLY_PHASE1","This pilot trial studies how well active surveillance and chemotherapy before surgery work in treating participants with stage II-III rectal cancer. Active surveillance involves monitoring participants for additional tumor growth after receiving cancer treatment. Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether deferring surgery after active surveillance and chemotherapy will work better in treating participants with stage II-III rectal cancer.",[103,104,105,106,107,108,109,110,111],"Rectal Adenocarcinoma","Stage II Rectal Cancer AJCC v8","Stage IIA Rectal Cancer AJCC v8","Stage IIB Rectal Cancer AJCC v8","Stage IIC Rectal Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","2026-05-18",{"date":114,"type":115},"2026-05-20","ACTUAL",{"date":117,"type":115},"2024-03-13",{"date":119,"type":97},"2026-10-31",{"name":5,"class":6},1]